Maintenance therapy with interferon alfa 2b in Hodgkin disease

Leukemia and Lymphoma

Volumn 30, Issue 5-6, 1998, Pages 651-656

  Avilés, Agustin ^a,b   Díaz Maqueo, José C ^a   Talavera, Alejandra ^a   Nambo, M Jesús ^a   García, Edna L ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b NONE   (Mexico)

Author keywords

Chemotherapy; Hodgkin's disease; Interferon

Indexed keywords

BLEOMYCIN; DACARBAZINE; EPIRUBICIN; RECOMBINANT ALPHA2B INTERFERON; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TIME;

EID: 0031851187     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809057577     Document Type: Article

References (23)

1. Longo, D. L. (1990). The use of chemotherapy in the treatment of Hodgkin's disease. Sem Oncol. 17, 716-735.
2. Longo, D. L., Duffey, P. L., Young, R. C. et al. (1992). Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy. The low probability of cure. J Clin Oncol, 10, 210-218.
3. Bierman, P. J., Bagin, R. G., Jagannath, S. et al. (1993) High-dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease. Long-term follow-up of 128 patients. Ann Oncol, 4, 767-771.
4. Fuchs, R., Löeffler, M., Pfreuncschuh, G. et al. (1994). Prognosis of high-dose chemotherapy autologous bone marrow transplation candidates no receiving this treatment after failure of primary therapy of Hodgkin's disease. Leuk Lymph, 14, 79-89.
5. Miller, D. S., Arthur, D. L., Litz, L. E. et al. (1994). Myelodysplastic syndrome after autologous bone marrow transplantation. An additional late complication of curative cancer therapy. Blood, 83, 3780-3786.
6. Traweek, S. T., Slovack, M. L., Nadena, E. E. et al. (1996). Myelodysplasia and acute myeloid leukemia ocurring after autologous bone marrow transplantation for lymphoma. Leuk Lymp, 20, 365-372.
7. Avilés, A., Arévila, N., Díaz-Maqueo, J. C. et al. (1993). Late cardiac toxicity of doxorubicin. epirubicin and mitoxantrone therapy for Hodgkin's disease in adults. Leuk Lymph, 11, 275-279.
8. Leavitt, R. D., Ratanatharatorn, V., Ozer, J. et al. (1987). Alfa 2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Sem Oncol, 14 (Suppl 2), 8-23.
9. Ryback, M., McCarroll, K. and Bernard, S. (1990). Interferon therapy of relapsed and refractory Hodgkin's disease. J Biol Respons Mod, 9, 1-4.
10. DelCarmen, M., Koziner, B. and Niborski, R. (1991). Recombinant interferon alfa 2b in patients with progressive and/or recurrent Hodgkin's disease. Leuk Lymph, 3, 439-441.
11. Atspodier, J. and Kircher, H. (1991). The outpatient use of recombinant human interleukin 2 and interferon alfa 2b in advances malignancies. Eur J Cancer, 27 (Suppl 4), 88-92.
12. Mazza, P., Zinzani, P. L., Pappa, G. et al. (1993). Alpha 2b recombinant interferon (Intron A in Hodgkin's lymphoma. Eur J Haematol, 45 (Suppl 45), 22-24.
13. Lukes, R. J. and Butler, J. J. (1966). The pathology and nomenclature of Hodgkin's disease. Cancer Res, 26, 1063-1083.
14. Carbone, P., Kaplan, H. S., Mushoff, K., Smithers, D. W. and Tubiana, M. (1976). Report of the Committee on Hodgkin's disease. Staging classification. Cancer Res, 38, 288-301.
15. Avilés, A., Díaz-Maqueo, J. C., Arévila, N. et al. (1989). Valoración de la función ventricular en pacientes tratados con mitoxantrone y epirubicina. Arch Inst Cardiol Méx, 59, 615-618.
16. Avilés, A., Guzmán, R., Talavera, A., García, E. L. and Díaz-Maqueo, J. C. (1994). Randomised study for the treatment of adult advanced Hodgkin's disease: epirubicin. vinblastine, bleomycin and dacarbazine (EBVD) versus mitoxantrone. vinblastine, bleomycin and dacarbazine (MBVD). Med Pediatr Oncol, 22, 168-172.
17. Kaplan, E. L. and Meier, P. (1958). Non parametric estimation from incomplete observations J Am Stat Assoc, 53, 457-481.
18. Mantel, N. (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50, 163-170.
19. World Helth Organization. (1979). WHO Handbook for Reporting results of cancer treatment. WHO Offset Publications No 48, Geneva, Switzerland.
20. Avilés, A., Fernández, R., Talavera, A. and Guzmán. R. (1995). The role of G-CSF as hematological support after myeloablative chemotherapy for refractory Hodgkin's disease. Cancer Res Ther Control, 4, 241-245.
21. Yahalom, R., Ryi, J., Strauss, D. J. et al. (1991). Impact of adjuvant radiation on the patterns and rate of relapse in advanced stage Hodgkin's disease treated with alternating chemotherapy combination. J Clin Oncol, 9, 2193-2201.
22. Somers, R., Carde, P., Henry-Amar, M. et al. (1994). A randomized study in stage IIIB and IV Hodgkin's disease comparing eight course of MOPP versus alternation of MOPP with ABVD. An European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre et Marie-Curie controlled clinical trial. J Clin Oncol, 12, 279-287.
23. Avilés, A., Díaz-Maqueo, J. C., García, E. L., Talavera, A. and Guzmán, R. (1992). Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma. Invest New Drugs, 10, 351-355.